GLP-1 Drugs and COPD: Can Mounjaro or Ozempic Help?

GLP-1 drugs are being studied in people with COPD, but the evidence does not establish Mounjaro or Ozempic as COPD treatments. Some studies report fewer flare-ups among users. Most evidence is observational, and the small randomized trial used liraglutide, not either of those brands.

Can you take Mounjaro or Ozempic if you have COPD?

COPD alone does not answer whether either medicine is appropriate. A person may have a separate indication, such as type 2 diabetes, that warrants a discussion with their clinician. The current US Mounjaro and Ozempic labels do not list COPD as an approved indication.

The practical distinction is between treating a qualifying metabolic condition in someone who also has COPD and prescribing a drug specifically to prevent COPD exacerbations. The research summarized below should not be used to choose a medicine or change inhalers without a clinical assessment.

Evidence by study design

Study	Design and population	What it can tell us
Liraglutide trial, 2022	40 people with obesity and COPD; randomized, placebo-controlled, 40 weeks	A small experimental test of selected lung and symptom outcomes
Foer and colleagues, 2023	Observational comparison in people with COPD and type 2 diabetes	Associations between diabetes drug classes and exacerbations
Tirzepatide cohort, 2026	Observational study with 6,055 people in each matched group	Associations with subsequent respiratory outcomes; not proof of causation

Sources: liraglutide trial, Foer study, tirzepatide cohort.

There has been a randomized COPD trial

The small liraglutide study used 3 mg for 40 weeks in participants with obesity and COPD. Investigators reported improvements in forced vital capacity, gas transfer and COPD Assessment Test scores. They did not find significant improvement in FEV1, the FEV1/FVC ratio or six-minute walking distance. Original trial.

This is a reason to investigate further. A study of 40 participants cannot settle whether GLP-1 drugs broadly reduce hospitalizations or deaths, and its results cannot simply be transferred to semaglutide or tirzepatide.

What the tirzepatide cohort found

The 2026 matched analysis reported an adjusted hazard ratio of 0.77 (95% CI 0.63–0.93) for acute COPD exacerbation. A hazard ratio compares event rates over follow-up; it is not a statement that every person's chance of a flare-up falls by 23 percentage points. Published results and methods.

Matching can balance measured characteristics. It cannot guarantee that groups are identical in smoking exposure, underlying disease severity, access to care or other factors that records capture imperfectly. The study therefore supports an association, not a confirmed protective drug effect.

The earlier Foer study also used an active-comparator observational design. Its comparisons concern people with both COPD and type 2 diabetes; they should not be generalized automatically to everyone with COPD. Original report.

What remains uncertain

A useful future trial would need to specify the drug, the COPD population, background inhaled treatment and a meaningful outcome such as moderate or severe exacerbations. It should also distinguish changes related to weight loss from other possible effects.

Questions to ask when reading a new headline:

1. Were participants randomly assigned, or were existing medical records compared?
2. Did everyone have obesity or diabetes as well as COPD?
3. Was the outcome a breathing test, a symptom score, a hospitalization or survival?
4. Were the follow-up periods and comparator treatments similar?
5. Were harms assessed alongside potential benefits?

A favorable result on one measure does not establish improvement on all the others.

Keep COPD care at the center

Established COPD care may include smoking cessation, prescribed inhaled medicines, pulmonary rehabilitation and other treatments matched to disease severity. A metabolic medicine is not a replacement for that plan. NHLBI treatment guidance.

If a clinician prescribes Mounjaro for a separate indication, our dose and missed-dose explainer and storage guide help readers interpret the product instructions. New severe abdominal symptoms also deserve assessment; see the separate gallbladder evidence review.

Sources and revision

Sources checked September 15, 2026. This update corrects the previous statement that no randomized COPD trial existed, removes unverified quotations and separates associations from proven treatment effects. Prepared by the editorial team with AI assistance; it is not an independent clinical guideline or physician review.